Status:
COMPLETED
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
Lead Sponsor:
GlaxoSmithKline
Conditions:
Lung Cancer, Small Cell
Eligibility:
All Genders
18+ years
Brief Summary
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan rem...
Eligibility Criteria
Inclusion
- Male or Female \>/= 18 years
- Diagnosis of small cell lung cancer
- Patient newly diagnosed with SCLC
- Has given written informed consent (if applicable)
Exclusion
- Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix.
- Patient presenting with recurrence of SCLC.
- Patients who has received any chemotherapy for the SCLC.
Key Trial Info
Start Date :
November 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00997061
Start Date
November 1 2009
End Date
February 1 2012
Last Update
February 3 2014
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Graz, Austria, A-8036
2
GSK Investigational Site
Innsbruck, Austria, A-6020
3
GSK Investigational Site
Salzburg, Austria, 5020
4
GSK Investigational Site
Vienna, Austria, 1130